688658 悦康药业
已收盘 09-11 15:00:00
资讯
新帖
简况
8月31日悦康药业跌6.10%，鹏华量化先锋混合基金重仓该股
证券之星 · 08-31
8月31日悦康药业跌6.10%，鹏华量化先锋混合基金重仓该股
8月28日悦康药业跌6.73%，鹏华量化先锋混合基金重仓该股
证券之星 · 08-28
8月28日悦康药业跌6.73%，鹏华量化先锋混合基金重仓该股
8月26日悦康药业涨6.67%，鹏华量化先锋混合基金重仓该股
证券之星 · 08-26
8月26日悦康药业涨6.67%，鹏华量化先锋混合基金重仓该股
悦康药业涨6.67%，开源证券一日前给出“买入”评级
证券之星 · 08-26
悦康药业涨6.67%，开源证券一日前给出“买入”评级
开源证券：给予悦康药业买入评级
证券之星 · 08-25
开源证券：给予悦康药业买入评级
8月24日悦康药业跌7.69%，鹏华量化先锋混合基金重仓该股
证券之星 · 08-24
8月24日悦康药业跌7.69%，鹏华量化先锋混合基金重仓该股
股市必读：悦康药业中报 - 第二季度单季净利润同比下降44.87%
证券之星 · 08-24
股市必读：悦康药业中报 - 第二季度单季净利润同比下降44.87%
悦康药业（688658）2026年中报简析：增收不增利
证券之星 · 08-22
悦康药业（688658）2026年中报简析：增收不增利
悦康药业(688658)6月30日股东户数1.56万户，较上期增加5.41%
证券之星 · 08-21
悦康药业(688658)6月30日股东户数1.56万户，较上期增加5.41%
图解悦康药业中报：第二季度单季净利润同比下降44.87%
证券之星 · 08-21
图解悦康药业中报：第二季度单季净利润同比下降44.87%
8月20日悦康药业涨19.98%，鹏华量化先锋混合基金重仓该股
证券之星 · 08-20
8月20日悦康药业涨19.98%，鹏华量化先锋混合基金重仓该股
悦康药业(688658.SH)子公司YKYY033注射液获得FDA临床试验批准
智通财经 · 08-12
悦康药业(688658.SH)子公司YKYY033注射液获得FDA临床试验批准
悦康药业YKYY017新适应症获批临床，广谱抗冠状病毒管线提速
新浪财经 · 08-10
悦康药业YKYY017新适应症获批临床，广谱抗冠状病毒管线提速
8月7日悦康药业涨7.31%，鹏华量化先锋混合基金重仓该股
证券之星 · 08-07
8月7日悦康药业涨7.31%，鹏华量化先锋混合基金重仓该股
悦康药业最新公告：YKYY017雾化吸入剂新增适应症获临床试验批准
证券之星 · 08-05
悦康药业最新公告：YKYY017雾化吸入剂新增适应症获临床试验批准
悦康药业（688658）披露控股股东股份解除冻结公告，8月4日股价上涨2.95%
证券之星 · 08-04
悦康药业（688658）披露控股股东股份解除冻结公告，8月4日股价上涨2.95%
7月27日悦康药业涨5.87%，鹏华量化先锋混合基金重仓该股
证券之星 · 07-27
7月27日悦康药业涨5.87%，鹏华量化先锋混合基金重仓该股
每周股票复盘：悦康药业（688658）YKYY033注射液新增五大适应症获批临床
证券之星 · 07-26
每周股票复盘：悦康药业（688658）YKYY033注射液新增五大适应症获批临床
7月24日悦康药业跌7.61%，鹏华量化先锋混合基金重仓该股
证券之星 · 07-24
7月24日悦康药业跌7.61%，鹏华量化先锋混合基金重仓该股
悦康药业(688658.SH)子公司YKYY033注射液新增适应症获批开展临床试验
智通财经 · 07-21
悦康药业(688658.SH)子公司YKYY033注射液新增适应症获批开展临床试验
加载更多
公司概况
公司名称：
悦康药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2020-12-24
主营业务：
悦康药业集团股份有限公司的主营业务是药品研发、生产制造、流通销售。公司的主要产品是心脑血管疾病药品、抗肿瘤药品、抗病毒药品、糖尿病药品、消化系统药品、生殖健康药品。公司多次荣获工信部医药工业百强和中国医药研发产品线最佳工业企业的殊荣。
发行价格：
24.36
{"stockData":{"symbol":"688658","market":"SH","secType":"STK","nameCN":"悦康药业","latestPrice":12.32,"timestamp":1789110000000,"preClose":12.72,"halted":0,"volume":11059180,"delay":0,"changeRate":-0.0314,"floatShares":450000000,"shares":450000000,"eps":-0.5966,"marketStatus":"已收盘","change":-0.4,"latestTime":"09-11 15:00:00","open":12.64,"high":12.64,"low":12.16,"amount":136000000,"amplitude":0.0377,"askPrice":12.33,"askSize":32,"bidPrice":12.32,"bidSize":473,"shortable":0,"etf":0,"ttmEps":-0.5966,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":5,"adr":0,"adjPreClose":12.72,"symbolType":"stock_kcb","openAndCloseTimeList":[[1789090200000,1789097400000],[1789102800000,1789110000000]],"highLimit":13.99,"lowLimit":11.45,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":450000000,"isCdr":false,"pbRate":1.73,"roa":"--","roe":"--","epsLYR":-0.59,"committee":0.522216,"marketValue":5544000000,"turnoverRate":0.0246,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-09-14。","afterMarket":{"amount":80203.2,"volume":6510,"close":12.32,"buyVolume":8490,"sellVolume":0,"time":1789112037746,"indexStatus":"已收盘 09-11 15:30:00","preClose":12.72},"floatMarketCap":5544000000},"requestUrl":"/m/hq/s/688658","defaultTab":"news","newsList":[{"id":"2663507592","title":"8月31日悦康药业跌6.10%，鹏华量化先锋混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2663507592","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663507592?lang=zh_cn&edition=full","pubTime":"2026-08-31 16:39","pubTimestamp":1788165590,"startTime":"0","endTime":"0","summary":"证券之星消息，8月31日悦康药业跌6.10%，收盘报13.4元，换手率4.73%，成交量21.28万手，成交额2.88亿元。重仓悦康药业的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为鹏华基金的鹏华量化先锋混合。鹏华量化先锋混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100022328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662068372","title":"8月28日悦康药业跌6.73%，鹏华量化先锋混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662068372","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662068372?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:36","pubTimestamp":1787906188,"startTime":"0","endTime":"0","summary":"证券之星消息，8月28日悦康药业跌6.73%，收盘报14.27元，换手率5.44%，成交量24.48万手，成交额3.59亿元。重仓悦康药业的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为鹏华基金的鹏华量化先锋混合。鹏华量化先锋混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800038070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662960707","title":"8月26日悦康药业涨6.67%，鹏华量化先锋混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662960707","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662960707?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:35","pubTimestamp":1787733304,"startTime":"0","endTime":"0","summary":"证券之星消息，8月26日悦康药业涨6.67%，收盘报14.72元，换手率7.13%，成交量32.09万手，成交额4.59亿元。重仓悦康药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为鹏华基金的鹏华量化先锋混合。鹏华量化先锋混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600036654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662796297","title":"悦康药业涨6.67%，开源证券一日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662796297","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662796297?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:34","pubTimestamp":1787733295,"startTime":"0","endTime":"0","summary":"今日悦康药业涨6.67%，收盘报14.72元。2026年8月25日，开源证券研究员余汝意,巢舒然发布了对悦康药业的研报《公司信息更新报告：2026H1业绩相对承压，前瞻布局mRNA肿瘤疫苗》，该研报对悦康药业给出“买入”评级。悦康药业个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600036650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662880785","title":"开源证券：给予悦康药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662880785","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662880785?lang=zh_cn&edition=full","pubTime":"2026-08-25 12:22","pubTimestamp":1787631721,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,巢舒然近期对悦康药业进行研究并发布了研究报告《公司信息更新报告：2026H1业绩相对承压，前瞻布局mRNA肿瘤疫苗》，给予悦康药业买入评级。 悦康药业 经营业绩相对承压，创新管线布局丰富，维持“买入”评级 2026H1公司实现营收11.81亿元，归母净利润-1.05亿元；扣非归母净利润-1.13亿元。最新盈利预测明细如下：本文数据来源于开源证券股份有限公司，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500024126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661217102","title":"8月24日悦康药业跌7.69%，鹏华量化先锋混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661217102","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661217102?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:35","pubTimestamp":1787560552,"startTime":"0","endTime":"0","summary":"证券之星消息，8月24日悦康药业跌7.69%，收盘报13.21元，换手率8.62%，成交量38.8万手，成交额5.24亿元。重仓悦康药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为鹏华基金的鹏华量化先锋混合。鹏华量化先锋混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400021946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661243244","title":"股市必读：悦康药业中报 - 第二季度单季净利润同比下降44.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661243244","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661243244?lang=zh_cn&edition=full","pubTime":"2026-08-24 01:11","pubTimestamp":1787505069,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，悦康药业报收于14.31元，下跌7.62%，换手率11.57%，成交量52.08万手，成交额7.44亿元。业绩披露要点：2026年第二季度单季度归母净利润为-7179.29万元，同比下降44.87%；扣非净利润为-7517.63万元，同比下降36.7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400000810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661218374","title":"悦康药业（688658）2026年中报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2661218374","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661218374?lang=zh_cn&edition=full","pubTime":"2026-08-22 06:07","pubTimestamp":1787350053,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期悦康药业发布2026年中报。根据财报显示，悦康药业增收不增利。截至本报告期末，公司营业总收入11.81亿元，同比上升1.18%，归母净利润-1.05亿元，同比下降6.14%。本次财报公布的各项数据指标表现一般。持有悦康药业最多的基金为鹏华量化先锋混合，目前规模为0.97亿元，最新净值1.7689，较上一交易日上涨0.86%，近一年上涨16.31%。本文数据来源于悦康药业2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200004881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661692992","title":"悦康药业(688658)6月30日股东户数1.56万户，较上期增加5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661692992","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661692992?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:40","pubTimestamp":1787305225,"startTime":"0","endTime":"0","summary":"证券之星消息，近日悦康药业披露，截至2026年6月30日公司股东户数为1.56万户，较3月31日增加799.0户，增幅为5.41%。在化学制药行业个股中，悦康药业股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.68万户。从股价来看，2026年3月31日至2026年6月30日，悦康药业区间跌幅为24.93%，在此期间股东户数增加799.0户，增幅为5.41%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100032343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661964239","title":"图解悦康药业中报：第二季度单季净利润同比下降44.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661964239","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661964239?lang=zh_cn&edition=full","pubTime":"2026-08-21 01:34","pubTimestamp":1787247244,"startTime":"0","endTime":"0","summary":"证券之星消息，悦康药业2026年中报显示，上半年度公司主营收入11.81亿元，同比上升1.18%；归母净利润-1.05亿元，同比下降6.14%；扣非净利润-1.13亿元，同比下降3.74%；其中2026年第二季度，公司单季度主营收入6.25亿元，同比上升5.95%；单季度归母净利润-7179.29万元，同比下降44.87%；单季度扣非净利润-7517.63万元，同比下降36.7%；负债率36.83%，投资收益296.58万元，财务费用719.53万元，毛利率55.75%。财报数据概要请见下图:本文数据来源于悦康药业2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100001266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660021104","title":"8月20日悦康药业涨19.98%，鹏华量化先锋混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660021104","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660021104?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:38","pubTimestamp":1787215127,"startTime":"0","endTime":"0","summary":"证券之星消息，8月20日悦康药业涨19.98%，收盘报15.49元，换手率2.95%，成交量13.27万手，成交额2.06亿元。重仓悦康药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为鹏华基金的鹏华量化先锋混合。鹏华量化先锋混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000028890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658927439","title":"悦康药业(688658.SH)子公司YKYY033注射液获得FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2658927439","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658927439?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:16","pubTimestamp":1786522575,"startTime":"0","endTime":"0","summary":"智通财经APP讯，悦康药业(688658.SH)发布公告，公司子公司北京悦康科创医药科技股份有限公司于近日获得美国食品药品监督管理局(简称“FDA”)关于同意YKYY033注射液用于预防和治疗动静脉血栓临床试验申请的函告。据悉，该产品已于2026年6月和7月获得国家药品监督管理局(NMPA)多项抗凝相关适应症的临床试验批准，临床Ⅰ期研究正在稳步推进中。本次顺利获得美国FDA临床试验许可，标志着产品正式取得海外临床开发资格。依托已获批的全场景血栓防治适应症矩阵，公司将开展多适应症差异化临床探索，精准对标全球主流抗凝治疗指南与临床标准，助力填补全球及国内高安全性、长效核酸类抗凝药物的市场空白。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478940.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BBC","BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658602316","title":"悦康药业YKYY017新适应症获批临床，广谱抗冠状病毒管线提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2658602316","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658602316?lang=zh_cn&edition=full","pubTime":"2026-08-10 12:14","pubTimestamp":1786335240,"startTime":"0","endTime":"0","summary":"近日，悦康药业集团股份有限公司公告称，其国际原创广谱冠状病毒膜融合抑制剂——YKYY017 雾化吸入剂，新增“治疗和预防人冠状病毒 OC43相关的呼吸道感染”适应症，正式获得国家药品监督管理局临床试验批准。在剂型设计上，YKYY017采用雾化吸入剂型，与口服及注射剂型形成显著差异化。YKYY017通过靶向冠状病毒S蛋白S2亚基高度保守的HR1区域，从源头抑制病毒与宿主细胞融合。此次YKYY017新适应症的获批，是悦康药业系统化管线矩阵战略落地的重要一环。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-08-10/doc-inimuzxr8228077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657161655","title":"8月7日悦康药业涨7.31%，鹏华量化先锋混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657161655","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657161655?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:43","pubTimestamp":1786092229,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日悦康药业涨7.31%，收盘报13.22元，换手率5.2%，成交量23.38万手，成交额2.98亿元。重仓悦康药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为鹏华基金的鹏华量化先锋混合。鹏华量化先锋混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657385510","title":"悦康药业最新公告：YKYY017雾化吸入剂新增适应症获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2657385510","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657385510?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:51","pubTimestamp":1785923470,"startTime":"0","endTime":"0","summary":"悦康药业(688658.SH)公告称，公司近日获得国家药监局核准签发的《药物临床试验批准通知书》，同意YKYY017雾化吸入剂用于治疗和预防人冠状病毒OC43相关呼吸道感染的临床试验。该药物为多肽类冠状病毒膜融合抑制剂，此前已获多国针对新冠感染的临床批件，本次新增适应症拓展了广谱抗病毒管线。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500032839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656552857","title":"悦康药业（688658）披露控股股东股份解除冻结公告，8月4日股价上涨2.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656552857","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656552857?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:15","pubTimestamp":1785852907,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，悦康药业报收于12.55元，较前一交易日上涨2.95%，最新总市值为56.48亿元。该股当日开盘12.29元，最高12.66元，最低12.25元，成交额达1.46亿元，换手率为2.6%。近日，悦康药业集团股份有限公司发布关于控股股东股份解除冻结的公告。本次解除冻结1,884,652股，占其持股比例的1.24%，占公司总股本的0.42%。本次解除冻结不会影响公司控制权稳定，亦不会对公司日常经营管理造成影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400041344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654988013","title":"7月27日悦康药业涨5.87%，鹏华量化先锋混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654988013","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654988013?lang=zh_cn&edition=full","pubTime":"2026-07-27 16:43","pubTimestamp":1785141783,"startTime":"0","endTime":"0","summary":"证券之星消息，7月27日悦康药业涨5.87%创60日新低，收盘报12.09元，换手率3.78%，成交量17.01万手，成交额2.03亿元。重仓悦康药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为鹏华基金的鹏华量化先锋混合。鹏华量化先锋混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700020997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654052250","title":"每周股票复盘：悦康药业（688658）YKYY033注射液新增五大适应症获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2654052250","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654052250?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:45","pubTimestamp":1785001515,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，悦康药业报收于11.42元，较上周的12.83元下跌10.99%。本周，悦康药业7月20日盘中最高价报13.41元。该药物为靶向凝血因子XI的GalNAc偶联siRNA药物，此前已获准开展预防术后静脉血栓形成的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653700319","title":"7月24日悦康药业跌7.61%，鹏华量化先锋混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653700319","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653700319?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:43","pubTimestamp":1784882586,"startTime":"0","endTime":"0","summary":"证券之星消息，7月24日悦康药业跌7.61%创60日新低，收盘报11.42元，换手率3.44%，成交量15.49万手，成交额1.83亿元。重仓悦康药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为鹏华基金的鹏华量化先锋混合。鹏华量化先锋混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028768.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653027383","title":"悦康药业(688658.SH)子公司YKYY033注射液新增适应症获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2653027383","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653027383?lang=zh_cn&edition=full","pubTime":"2026-07-21 17:22","pubTimestamp":1784625724,"startTime":"0","endTime":"0","summary":"智通财经APP讯，悦康药业 发布公告，公司子公司北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司于近日获得国家药品监督管理局核准签发的关于YKYY033注射液新增适应症的《药物临床试验批准通知书》，公司将开展本品I期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688658","IBBJ","IBBQ","BMED","BK0239","PSYK","MDTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789256172252,"stockEarnings":[{"period":"1week","weight":-0.0901},{"period":"1month","weight":-0.0792},{"period":"3month","weight":-0.0888},{"period":"6month","weight":-0.3148},{"period":"1year","weight":-0.5064},{"period":"ytd","weight":-0.4551}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"悦康药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15563人(较上一季度增加5.41%)","perCapita":"28914股","listingDate":"2020-12-24","address":"北京市大兴区北京经济技术开发区宏达中路6号","registeredCapital":"45000万元","survey":" 悦康药业集团股份有限公司的主营业务是药品研发、生产制造、流通销售。公司的主要产品是心脑血管疾病药品、抗肿瘤药品、抗病毒药品、糖尿病药品、消化系统药品、生殖健康药品。公司多次荣获工信部医药工业百强和中国医药研发产品线最佳工业企业的殊荣。","listedPrice":24.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"悦康药业(688658)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供悦康药业(688658)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"悦康药业,688658,悦康药业股票,悦康药业股票老虎,悦康药业股票老虎国际,悦康药业行情,悦康药业股票行情,悦康药业股价,悦康药业股市,悦康药业股票价格,悦康药业股票交易,悦康药业股票购买,悦康药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"悦康药业(688658)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供悦康药业(688658)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}